Pharmatek Expands Packaging Services
News Oct 17, 2013
Pharmatek has announced the installation and qualification of an automated bottling line at its cGMP facility in San Diego, CA.
The addition of the line is part of the Company’s ongoing investment to support the increasing customer demand for larger scale productions. The line will be fully operational in November 2013.
The bottling line provides maximum flexibility and is beneficial for both small and large volume clinical packaging projects.
Manufactured by CVC Technologies, the line includes a Cremer electronic channel counter, capper, induction sealer, re-torquer and high speed wrap labeler. The system is integrated with a CVC electronic conveyor system and redundant quality inspection stations.
Automatic bottling improves the efficiency and accuracy of clinical packaging, resulting in a reduction in overall costs and time-to-clinic.
Additionally, the new bottling line significantly increases Pharmatek’s overall capacity, allowing higher throughput and larger GMP manufacturing runs.
“Our investment in automated clinical packaging illustrates our commitment to our customers’ need for strategies that streamline supply chain management and speed supplies to the clinic,” said Pharmatek president Tim Scott. “This is an important enhancement to our offering, enabling us to continue to support our customers throughout their development program and into larger scale operations.”
Pharmatek offers primary packaging of tablets and capsules in HDPE bottles. The Company supports secondary packaging, cold chain management, including storage and distribution, and stability testing.
Complex labeling requirements, such as foreign language labels, blinding and booklet- labeling, are also accommodated.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE